Table 2.
Effects of 4- and 12-week treatment of pitavastatin (PTV) and atorvastatin (ATV) on lipid profiles, systemic biomarkers and endothelial progenitor cells
| |
Baseline |
4 weeks |
12 weeks |
PTV# |
ATV# |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PTV | ATV | P-value | PTV | ATV | P-value | PTV | ATV | P-value | P-value | P-value | |
| WBC (/cumm) |
6223 ± 1790 |
7184 ± 1563 |
0.16 |
6784 ± 2106 |
7238 ± 1180 |
0.50 |
6338 ± 1809 |
6930 ± 1245 |
0.34 |
0.73 |
0.82 |
| Glucose (mmol/L) |
6.98 ± 1.39 |
6.28 ± 1.04 |
0.16 |
7.12 ± 1.71 |
6.54 ± 1.23 |
0.39 |
7.58 ± 2.54 |
6.54 ± 1.05 |
0.18 |
0.71 |
0.80 |
| HOMA-IR |
1.9 ± 1.2 |
2.0 ± 1.0 |
0.78 |
|
|
|
5.2 ± 4.8 |
3.9 ± 2.8 |
0.41 |
0.05 |
<0.05 |
| hs-CRP (mg/dL) |
0.18 ± 0.18 |
0.35 ± 0.37 |
0.16 |
0.17 ± 0.11 |
0.16 ± 0.19 |
0.90 |
0.20 ± 0.20 |
0.17 ± 0.20 |
0.88 |
0.93 |
0.17 |
| TC (mmol/L) |
5.20 ± 0.69 |
5.24 ± 0.64 |
0.89 |
3.73 ± 0.53 |
3.62 ± 0.36 |
0.53 |
3.65 ± 0.52 |
3.56 ± 0.37 |
0.58 |
<0.05 |
<0.05 |
| TG (mmol/L) |
1.53 ± 0.71 |
1.72 ± 0.59 |
0.46 |
1.25 ± 0.58 |
1.26 ± 0.28 |
0.94 |
1.15 ± 0.51 |
1.22 ± 0.39 |
0.72 |
0.26 |
<0.05 |
| LDL-c (mmol/L) |
3.70 ± 0.55 |
3.82 ± 0.85 |
0.68 |
2.12 ± 0.46 |
2.19 ± 0.45 |
0.68 |
2.14 ± 0.33 |
2.09 ± 0.51 |
0.76 |
<0.05 |
<0.05 |
| HDL-c (mmol/L) |
1.25 ± 0.25 |
1.18 ± 0.19 |
0.38 |
1.29 ± 0.33 |
1.18 ± 0.18 |
0.32 |
1.25 ± 0.28 |
1.19 ± 0.20 |
0.58 |
0.92 |
0.96 |
| NOx (μmol/L) |
70.8 ± 42.5 |
78.5 ± 96.8 |
0.80 |
75.3 ± 66.1 |
80.6 ± 62.9 |
0.85 |
79.5 ± 86.1 |
68.9 ± 46.4 |
0.71 |
0.95 |
0.91 |
| IL-10 (pg/ml) |
1.8 ± 1.2 |
1.5 ± 0.8 |
0.48 |
2.1 ± 1.6 |
2.1 ± 1.4 |
0.91 |
2.07 ± 1.6 |
1.7 ± 1.8 |
0.57 |
0.87 |
0.55 |
| TNF-α (pg/ml) |
3.6 ± 1.7 |
4.0 ± 2.8 |
0.67 |
3.3 ± 1.8 |
4.5 ± 2.8 |
0.22 |
2.8 ± 0.8 |
4.3 ± 3.2 |
0.12 |
0.45 |
0.91 |
| ADMA (μmol/L) |
0.61 ± 0.10 |
0.68 ± 0.10 |
0.09 |
|
|
|
0.56 ± 0.12 |
0.53 ± 0.12 |
0.55 |
0.25 |
<0.05 |
| SDF-1α (pg/ml) |
2619.9 ± 640.5 |
2851.4 ± 669.1 |
0.38 |
2673.5 ± 774.6 |
3043.3 ± 733.5 |
0.24 |
2603.6 ± 757.1 |
3085.5 ± 701.1 |
0.16 |
0.98 |
0.668 |
| VEGF (pg/ml) |
74.33 ± 32.26 |
69.86 ± 31.53 |
0.72 |
118.36 ± 50.05 |
67.65 ± 42.85 |
0.01 |
98.65 ± 46.64 |
74.04 ± 29.33 |
0.12 |
<0.05 |
0.898 |
| EPC level (%) |
|
|
|
|
|
|
|
|
|
|
|
| CD34+KDR+ | 0.021 ± 0.015 | 0.039 ± 0.039 | 0.16 | 0.035 ± 0.031 | 0.029 ± 0.024 | 0.59 | 0.054 ± 0.044 | 0.043 ± 0.029 | 0.45 | <0.05 | 0.57 |
Values are mean ± standard deviation. #: Difference between baseline, 4 weeks and 12 weeks of treatment in the same group. WBC: white blood cell; HOMA-IR: Homeostasis model of assessment-insulin resistance; TC: total cholesterol; TG: Triglyceride; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; hs-CRP: high sensitivity C-reactive protein; NOx: total nitric oxide; IL-10: interleukin-10; TNF-α: tumor necrosis factor-α; ADMA: asymmetric dimethylarginine; SDF-1α: stromal cell-derived factor-1α; VEGF: vascular endothelial growth factor; EPC: endothelial progenitor cell.